Focused On-demand Library for Ribosomal biogenesis protein LAS1L

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y4W2

UPID:

LAS1L_HUMAN

Alternative names:

Protein LAS1 homolog

Alternative UPACC:

Q9Y4W2; A9X410; Q5JXQ0; Q8TEN5; Q9H9V5

Background:

Ribosomal biogenesis protein LAS1L, also known as Protein LAS1 homolog, plays a crucial role in the biogenesis of the 60S ribosomal subunit, essential for protein synthesis. It is pivotal in the maturation of the 28S rRNA and operates as part of the 5FMC complex, influencing gene transactivation through desumoylation processes.

Therapeutic significance:

The protein's involvement in Intellectual developmental disorder, X-linked, syndromic, Wilson-Turner type, underscores its therapeutic significance. Understanding the role of Ribosomal biogenesis protein LAS1L could open doors to potential therapeutic strategies for this neurologic disorder, offering hope for targeted interventions.